New stock news | Keji second submission to the Hong Kong Stock Exchange

According to the Zhixiong Finance and Economics App, it was disclosed by the Hong Kong Stock Exchange on June 30 that Ke Li Limited (referred to as Ke Li) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with China International Capital Corporation Limited () as its sole sponsor. The company had previously submitted a listing application to the Hong Kong Stock Exchange on December 18, 2025. According to Frost & Sullivan data, based on 2025 revenue, Ke Li ranks among the top ten in the Chinese pharmaceutical marketing, promotion, and sales market, with a market share of approximately 2.0%. According to the same data, based on 2025 revenue calculation, the company is the largest provider of pediatric pharmaceutical marketing, promotion, and sales services in China, holding approximately 17.0% of the market share.